VG2D Pharma has begun its search for seed funding in the amount of €555,000. The company is currently preparing to move into clinical trials, scheduled for 2026/2027, and is in the process of raising funds from private investors.
Amount sought: €555,000
Ongoing series: SEED
Startup contact: Imane Wild, CEO; i.wild@vg2dpharma.fr
Theme: Health - Therapeutics
Applications: Therapeutic Development
Partnerships and Awards: *I-lab 2024 *BFTE Grant (BPI France)
Laboratory: ICMR/ BIOS / COBRA
Institutions: University of Reims Champagne-Ardenne (URCA) / University of Rouen
Intellectual property: 1 PATENT
Technology
The MucoPyf project focuses on the development of a new treatment for cystic fibrosis. The novelty of the invention lies in the molecules’ ability to restore the function of the defective CFTR channel, combined with an anti-inflammatory effect.
Applications
Treatment of cystic fibrosis
Benefits
A unique mechanism of action offering significant benefits: - Broad-spectrum efficacy: The molecules have been designed to treat mutations of types II through VI; this flagship product family expands the range of effective treatments... - Optimized dosing: A simplified regimen of one oral tablet promotes adherence and improves patients’ quality of life. - Cost reduction: Through efficient production, we aim to expand access to treatments and reduce financial burdens.
Maturity
- Preclinical phase in progress - Preparing for clinical phases 1 and 2
For more information
Contact your dedicated advisor